

## **SARS-CoV-2 entry related genes are comparably expressed in children's lung as adults**

Yue Tao<sup>1, #</sup>, Ruwen Yang<sup>1, #</sup>, Chen Wen<sup>2, #</sup>, Jue Fan<sup>3</sup>, Jing Ma<sup>4</sup>, Qiao He<sup>4</sup>, Zhiguang Zhao<sup>5</sup>, Xinyu Song<sup>6</sup>, Hao Chen<sup>2</sup>, Guocheng Shi<sup>2</sup>, Minzhi Yin<sup>4</sup>, Nan Fang<sup>3</sup>, Hao Zhang<sup>2, \*</sup>, Huiwen Chen<sup>2, \*</sup>, Xi Mo<sup>1, \*</sup>

*<sup>1</sup>The Laboratory of Pediatric Infectious Diseases, Pediatric Translational Medicine Institute, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China*

*<sup>2</sup>Department of Cardiothoracic Surgery, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China*

*<sup>3</sup>Singleron Biotechnologies, Yaogu Avenue 11, Nanjing, Jiangsu Province, China*

*<sup>4</sup>Department of Pathology, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China*

*<sup>5</sup>Department of Pathology, the Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, China*

*<sup>6</sup> Department of Cardiothoracic Surgery, the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China*

*#* These authors contribute equally to this work.

*\** Corresponding Authors:

xi.mo@shsmu.edu.cn;

chenhuiwen@scmc.com.cn;

drzhanghao@126.com

## Abstract

**To explore whether the expression levels of viral-entry associated genes might contribute to the milder symptoms in children, we analysed the expression of these genes in both children and adults' lung tissues by single cell RNA sequencing (scRNA-seq) and immunohistochemistry (IHC). Both scRNA-seq and IHC analyses showed comparable expression of the key genes for SARS-CoV-2 entry in children and adults, including *ACE2*, *TMPRSS2* and *FURIN*, suggesting that instead of lower virus intrusion rate, other factors are more likely to be the key reasons for the milder symptoms of SARS-CoV-2 infected children.**

Since December 2019, a novel coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread rapidly<sup>1</sup> and posed a severe threat to global public health<sup>2</sup>. As of 18 May 2020, this disease, named coronavirus disease 2019 (COVID-19), had caused 4,618,821 confirmed cases and 311,847 deaths globally, indicating SARS-CoV-2 as a highly contagious virus<sup>3</sup>.

Available data, although limited, suggest that the SARS-CoV-2 infection in children is relatively rare and less severe compared to that in adults<sup>4,5</sup>. However, a recent study pointed out that children are just as likely to be infected by SARS-CoV-2 as adults when exposed to similar environment. Among all children under 10 who had close contact with confirmed cases, the infection rate was 7.4%, which is comparable to that of the whole population average (7.9%)<sup>6</sup>. The latest guidelines also state that all individuals, including children, are generally susceptible to SARS-CoV-2<sup>7</sup>. In the meantime, the low incidence of critical illness in children has been reported repeatedly and accepted widely while the underlying mechanism remains to be elucidated.

Currently, there are two major speculations regarding why children display milder symptoms during the infection: relatively lower expression of viral-entry associated genes compared to adults and immune-related factors<sup>8</sup>. Angiotensin converting enzyme 2 (*ACE2*), a type I membrane protein expressed in various types of organs, has been proven to be the key receptor of SARS-CoV-2 for cellular entry via its interaction with the spike (S) protein<sup>9</sup> of the virus, which is cleaved by transmembrane protease serine 2 (*TMPRSS2*)<sup>10</sup>. But it is worth noting that

simultaneously blocking the activity of TMPRSS2 and the cysteine proteases CATHEPSIN B/L cannot completely inhibit the entry of SARS-CoV-2 *in vitro*, suggesting the possible involvement of additional proteases in the priming of SARS-CoV-2<sup>10</sup>. A FURIN cleavage site has been identified at S1/S2 boundary in the SARS-CoV-2 S protein<sup>11</sup>, which is suggested to be potentially cleaved by FURIN<sup>12</sup> as an additional possible mechanism for the priming of the virus. Therefore, in the present study, the expression levels of viral-entry associated genes (*i.e.*, *ACE2*, *TMPRSS2* and *FURIN*) in both children and adults' lung tissues were analyzed by single-cell RNA sequencing (scRNA-seq) and immunohistochemistry (IHC) to explore whether the expression levels of these genes might contribute to the milder symptoms in children.

Non-affected lung tissues from four children with congenital heart disease combined with lung diseases requiring lobectomies were collected (Fig. 1A, Supplementary Table S1), and the transcriptome of totally 16,530 cells were analyzed via scRNA-seq. The cells were clustered and annotated into 15 cell types with major cell types known to exist in lung identified (Fig. 1B). When compared to a public dataset (GSE122960) of eight adult lung donors (totally 42,843 cells)<sup>13</sup>, although fewer cells were obtained from children's lung tissues, the cell subtypes in children were the same as those in adults (Fig. 1B). Consistent with previous analyses<sup>14,15</sup>, AT2 cells were the major cell type expressing *ACE2*. Other lung/bronchiolar epithelial cells, such as club cells in adults and AT1 cells in children also showed noticeable expression of *ACE2*. Similarly, the AT2, AT1 and club cells were the major cell types with relatively high expression of *TMPRSS2* in both adults and children. The expression pattern of *FURIN*, however, differed from *ACE2* and *TMPRSS2*, with EC cells and monocyte being the major expressing cell types in adults but AT2 and club cells in children (Fig. 1D). In general, no significant changes were observed in the expression levels of *ACE2*, *TMPRSS2* and *FURIN* between adults and children, although the percentage of cells expressing *TMPRSS2* and *FURIN* were higher in adults than children (Fig. 1C).

To further verify the expression of *ACE2*, *TMPRSS2* and *FURIN* at the protein level, IHC was performed in the lung biopsy specimens from children and adults in two independent cohorts (Supplementary Table S2). Consistent with the scRNA-seq analysis, the overall expression levels of *ACE2* in children and adults were comparable in both cohorts, with a very small portion of the lung cells expressing *ACE2*. However, *TMPRSS2* and *FURIN* both showed higher expression

level in children compared to adults, although the former did not reach statistical significance (Fig. 2, Supplementary Fig. S1). The underlying reasons for the partial discrepancy between the results from scRNA-seq and IHC could be the complicated processes downstream of transcription including post-transcriptional, translational and degradation regulations<sup>16</sup>. Meanwhile, the semi-quantitative characteristics of IHC and its limitation in identifying cell types may also contribute to such discrepancies, which further emphasize the necessity to combine these methods for an impartial interpretation of the results. Besides, in accordance with the previous report, the staining patterns of ACE2, TMPRSS2 and FURIN were consistent in the same types of tissue regardless of the pathological condition of the patient<sup>17</sup>.

Different coronaviruses employ distinct domains within the S1 subunit of S protein to recognize unique entry receptors. SARS-CoV and SARS-CoV-2 interact directly with ACE2 via S domain B to enter the target cells<sup>11,18</sup>, while MERS-CoV utilizes dipeptidyl peptidase 4 (DPP4) as its cellular receptor via S domain A<sup>19</sup>. Both SARS-CoV and MERS-CoV use TMPRSS2 and CATHEPSIN B/L during the priming process. In addition, MERS-CoV S protein can be activated by proprotein convertases and FURIN depending on the host cell and tissue types<sup>20,21</sup>. Although the S proteins of SARS-CoV and SARS-CoV-2 share 76% sequence identity<sup>22</sup>, SARS-CoV-2 S protein harbors a FURIN cleavage site that is absent in SARS-CoV, suggesting its potential cleavage by FURIN<sup>12</sup>.

ACE2 is enriched in the heart, kidney and testis, and is also broadly distributed in the lung, liver, intestine and brain<sup>23</sup>. It is well accepted that the lung is the primary target organ of SARS-CoV-2 infection<sup>24,25</sup>. An analysis of the scRNA-seq data obtained from 43,134 human lung cells showed that *ACE2* was expressed in 0.64 % of all cells in lungs and 83% of the *ACE2* expression was found in AT2 cells, indicating that AT2 is the primary target of SARS-CoV-2 in the lungs<sup>26</sup>, which is consistent with our results. Although children of all ages are susceptible to COVID-19, accumulating clinical data indicated better clinical outcomes in children compared to adults. However, the expression and the activity of ACE2 during the development of children and teenagers are largely unclear<sup>24,27</sup>. Data from animal models remain controversial so far. *ACE2* expression in the lungs was reported to decrease during aging in a study performed in aged rats<sup>28</sup> and another study using sheep as model revealed significantly lower expression of *ACE2* in the neonatal sheep comparing to that in the adult ones<sup>29</sup>.

The present study showed comparable expression levels of ACE2, as well as other factors involved in SARS-CoV-2 cellular entry, in children and adults, suggesting that the expression level of viral-entry associated genes is unlikely to be the key reason for milder symptoms in children. Instead, other factors such as unique features in children immunity may play a more important role. Children have a distinct immune profile during infections because their immune system is still under development. It has been shown that compared to adults, decreased mononuclear and polymorphonuclear chemotaxis is found in children and such decrease remains significant until the age of 16<sup>30</sup>. In the meantime, frequent exposure to a plethora of other pathogens, such as respiratory syncytial virus (RSV), would repeatedly challenge the innate immunity including the age dependent maturation of the interferon response<sup>31-34</sup>, possibly leading to an enhanced innate immune function which is one feature of trained immunity<sup>8,35</sup>. Taken together, unique features in children immunity could be a possible explanation for the milder symptoms and lower mortality rate in children SARS-CoV-2 infections.

In summary, the present study, for the first time, described the features of children's lungs by scRNA-seq. Both scRNA-seq and IHC analyses showed comparable, if not higher, expression of the key genes for SARS-Cov-2 entry, including *ACE2*, *TMPRSS2* and *FURIN*, suggesting that instead of lower virus intrusion rate, other factors are more likely to be the key reasons for the milder symptoms of SARS-CoV-2 infected children, which awaits further investigation.

**Fig. 1 Expression of *ACE2*, *TMPRSS2* and *FURIN* across different cell types in the lung samples from children and adults determined by scRNA-seq.** (A) Schematic illustration of the representative sampling locations of the surgical lung specimens from children used in this study and an overview of major cell types detected in the specimens. AT1: alveolar type I; AT2: alveolar type II; DC: dendritic cell; RBC: red blood cell; EC: endothelial cell. Graphic components were obtained and adapted from Library of Science and Medical Illustrations (<http://www.somersault1824.com>). (B) UMAP (Uniform manifold approximation and projection) visualization of an integrated scRNA-seq dataset consists of data from GSE122960 and sequencing results from four children lung specimens. 15 clustered and annotated cell types are color-coded (upper panel), while cells from adults and children are distinguished with blue dots representing cells from adults and red dots representing cells from children (lower panel). SMC: vascular smooth muscle cell. (C) Expression levels of *ACE2*, *TMPRSS2* and *FURIN* in the lung samples. Average expression level in each sample, percentage of expressing cells in each sample,

and expression level of each cell were plotted (from left to right). Error bar represents standard deviation and *t*-test was used for statistical analysis. Significance of difference is reflected by the *p*-value shown in the plots. (D) Dot-plot illustrating expression of *ACE2*, *TMPRSS2* and *FURIN* across all 15 cell types in the lung samples. Dot color represents the Z-score normalized average gene expression within each particular cell type. Dot size represents the percentage of cells expressing the respective genes within each cell type. Given the extremely high expression of *ACE2* in lymphatic EC in children's lung samples, these data points were excluded from the dot-plot for proper visualization of the general view of *ACE2* expression in the majority of the cell types. The complete dataset used for generation of this figure are listed in Supplementary Table S3.





**Fig. 2 Expression of ACE2, TMPRSS2 and FURIN in the lung samples from children and adults determined by immunohistochemistry (IHC).** Sections (4 μm) of formalin-fixed, paraffin-embedded (FFPE) lung tissues from adults and children were subjected to standard IHC protocols to analyze the expression levels of *ACE2* and *TMPRSS2* (cohort 1) as well as *ACE2* and *FURIN* (cohort 2). Tissues for positive controls of various antibodies are: testis for *ACE2*, prostate for *TMPRSS2* and kidney for *FURIN*. The graphs are IHC representatives from both cohorts, with the patient number indicated.

#### References:


1. Chen, N., *et al.* Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* **395**, 507-513 (2020).
2. WHO Director-General's opening remarks at the media briefing on COVID-19 – 11 March 2020. <https://www.who.int/dg/speeches/detail/who-director-general-s-openingremarks-at-the-media-briefing-on-covid-19-11-march-2020>.
3. WHO. Coronavirus disease 2019 (COVID-19) Situation Report – 119. [https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200518-covid-19-sitrep-119.pdf?sfvrsn=4bd9de25\\_4](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200518-covid-19-sitrep-119.pdf?sfvrsn=4bd9de25_4) Date last updated: May 18, 2020.
4. Dong, Y., *et al.* Epidemiology of COVID-19 Among Children in China. *Pediatrics* (2020).
5. She, J., Liu, L. & Liu, W. COVID-19 epidemic: Disease characteristics in children. *J Med Virol* (2020).
6. Bi, Q., *et al.* Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study. *Lancet Infect Dis* (2020).
7. National Health commission of the People's Republic of China. Diagnosis and treatment of novel coronavirus pneumonia (trial version 7 revised version). [2020-03-03]. <http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml>.
8. Cristiani, L., *et al.* Will children reveal their secret? The coronavirus dilemma. *Eur Respir J* **55**(2020).

9. Yan, R., *et al.* Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. *Science* **367**, 1444-1448 (2020).
10. Hoffmann, M., *et al.* SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell* **181**, 271-280 e278 (2020).
11. Walls, A.C., *et al.* Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. *Cell* **181**, 281-292 e286 (2020).
12. Coutard, B., *et al.* The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. *Antiviral Res* **176**, 104742 (2020).
13. Reyfman, P.A., *et al.* Single-Cell Transcriptomic Analysis of Human Lung Provides Insights into the Pathobiology of Pulmonary Fibrosis. *Am J Respir Crit Care Med* **199**, 1517-1536 (2019).
14. Lukassen, S., *et al.* SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells. *EMBO J* **39**, e105114 (2020).
15. Zou, X., *et al.* Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. *Front Med* **14**, 185-192 (2020).
16. Christine, V., *et al.* Insights Into the Regulation of Protein Abundance From Proteomic and Transcriptomic Analyses. *Nat Rev Genet* **13**, 227-232 (2012).
17. Hamming, I., *et al.* Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. *J Pathol* **203**, 631-637 (2004).
18. Ge, X.Y., *et al.* Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. *Nature* **503**, 535-538 (2013).
19. Raj, V.S., *et al.* Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. *Nature* **495**, 251-254 (2013).
20. Kawase, M., Shirato, K., van der Hoek, L., Taguchi, F. & Matsuyama, S. Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry. *J Virol* **86**, 6537-6545 (2012).
21. Du, L., *et al.* MERS-CoV spike protein: a key target for antivirals. *Expert Opin Ther Targets* **21**, 131-143 (2017).
22. Wu, C., *et al.* Furin, a potential therapeutic target for COVID-19. *chinaRxiv* <https://doi.org/10.12074/202002.00062>. (2020).
23. Kuba, K., Imai, Y., Ohto-Nakanishi, T. & Penninger, J.M. Trilogy of ACE2: a peptidase in the renin-angiotensin system, a SARS receptor, and a partner for amino acid transporters. *Pharmacol Ther* **128**, 119-128 (2010).
24. Guan, W.J., *et al.* Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med* **382**, 1708-1720 (2020).
25. Yang, X., *et al.* Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Respir Med* **8**, 475-481 (2020).
26. Zhao, Y., *et al.* Single-cell RNA expression profiling of ACE2, the receptor of SARS-CoV-2. *bioRxiv* <https://doi.org/10.1101/2020.01.26.919985>. (2020).
27. Li, Q., *et al.* Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. *N Engl J Med* **382**, 1199-1207 (2020).
28. Xie, X., Chen, J., Wang, X., Zhang, F. & Liu, Y. Age- and gender-related difference of ACE2 expression in rat lung. *Life Sci* **78**, 2166-2171 (2006).

29. Chen, K., Bi, J., Su, Y., Chappell, M.C. & Rose, J.C. Sex-Specific Changes in Renal Angiotensin-Converting Enzyme and Angiotensin-Converting Enzyme 2 Gene Expression and Enzyme Activity at Birth and Over the First Year of Life. *Reprod Sci* **23**, 200-210 (2016).
30. Klein, R.B., *et al.* Decreased mononuclear and polymorphonuclear chemotaxis in human newborns, infants, and young children. *Pediatrics* **60**, 467-472 (1977).
31. Marr, N., *et al.* Attenuation of respiratory syncytial virus-induced and RIG-I-dependent type I IFN responses in human neonates and very young children. *J Immunol* **192**, 948-957 (2014).
32. Simon, A.K., Hollander, G.A. & McMichael, A. Evolution of the immune system in humans from infancy to old age. *Proc Biol Sci* **282**, 20143085 (2015).
33. Bogunovic, D. Type I Interferons in Newborns-Neurotoxicity versus Antiviral Defense. *mBio* **7**(2016).
34. Hijano, D.R., *et al.* Role of Type I Interferon (IFN) in the Respiratory Syncytial Virus (RSV) Immune Response and Disease Severity. *Front Immunol* **10**, 566 (2019).
35. Brodin, P. Why is COVID-19 so mild in children? *Acta Paediatr* **109**, 1082-1083 (2020).


**A****B****C****D**

**ACE2**




**Testis**

**TMPRSS2**




**Prostate**

**FURIN**




**Kidney**




**Adult-A#3 in cohort1**




**Adult-A#3 in cohort1**




**Adult-A#8 in cohort2**




**Adult-A#7 in cohort1**




**Adult-A#7 in cohort1**




**Adult-A#9 in cohort2**



**Child-C#1 in cohort1**




**Child-C#1 in cohort1**




**Child-C#1 in cohort2**



**Child-C#4 in cohort1**



**Child-C#4 in cohort1**



**Child-C#8 in cohort2**